Avalo Therapeutics

One mission. Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs.

[Avalo Therapeutics @Avalotx]

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

https://t.co/vMQuvJC1dt

#PressRelease #InvestorRelations #News #Growth #StockMarket #FTSE #Russell2000 #Russell3000 #IndexFunds #Healthcare #Biotech #AVTX

[Avalo Therapeutics @Avalotx]

Avalo Therapeutics Announces Pricing of $375 Million Public Offering

Read the full press release here: https://t.co/7sZSxbnFeu

[Avalo Therapeutics @Avalotx]

Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

Read full press release here: https://t.co/Wp4efGKV7O

[Avalo Therapeutics @Avalotx]

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa :: Avalo Therapeutics, Inc. (AVTX) (https://t.co/1UoloGZkxT)

[Avalo Therapeutics @Avalotx]

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million :: Avalo Therapeutics, Inc. (AVTX) (https://t.co/1UoloGYMIl)

[Avalo Therapeutics @Avalotx]

Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board
https://t.co/ZKUPmJej44

[Avalo Therapeutics @Avalotx]

Garry A. Neil, M.D., CEO and Chairman of the Board of Avalo Therapeutics will attend and present at the ATS 2023 Respiratory Innovation Summit (RIS), hosted by the American Thoracic Society, on May 19-20, 2023 in Washington, DC. https://t.co/Q0RUt2sV2M #ATS2023 #RIS

[Avalo Therapeutics @Avalotx]

Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023
https://t.co/wgqfd1MR8m

[Avalo Therapeutics @Avalotx]

Data from our 83-pt Phase 2 trial of AVTX-002 (formerly CERC-002), our anti-LIGHT antibody, in COVID ARDS patients was just published in the print version of JCI https://t.co/o1mnprMHLB (please see our disclaimer https://t.co/B375mcenXe)

[Avalo Therapeutics @Avalotx]

As we look ahead at 2022, we’re committed to continuing to advance our multiple product candidates in clinical development in the hopes of delivering highly targeted therapies in areas of significant unmet clinical need. Learn more: https://t.co/MzMUJEFJ0v #precisionmedicine

[Avalo Therapeutics @Avalotx]

During our Investor Day, we announced positive results from our Phase 1 trial of AVTX-002 in adults with moderate to severe #Crohnsdisease. These results validate this treatment’s broad potential in inflammatory disease. Learn more here: https://t.co/MzMUJEFJ0v #investorday

[Avalo Therapeutics @Avalotx]

At Avalo, we're committed to developing innovative treatments that have meaningful impact on the lives of patients with serious and rare diseases. Read more about how we're advancing our rich pipeline of six clinical candidates with broad clinical utility.

[Avalo Therapeutics @Avalotx]

Introducing Avalo Therapeutics - a precision medicine company delivering targeted therapies to patients with unmet need. Learn more about our pipeline of novel, targeted therapies in immunology, immune-oncology, and rare genetic diseases.

[Avalo Therapeutics @Avalotx]

Phase 2 clinical trial of CERC-002 in patients hospitalized with COVID-19 ARDS met its primary endpoint. This clinical stage product
significantly reduced respiratory failure and mortality, resulting in a 50% trend towards reduction in overall mortality. https://t.co/PqUNNJbld7